Research Phase

 
News Articles for Research Phase top ^
2014/12/2
New and Updated Results Show 50% Response Rate in 14 Cardiac-Evaluable Patients New Data Show 43% Best Response Rate in 14 Renal-Evaluable Patients Cardiac and Renal Biomarker Responses of Single-Agent NEOD001-Treated Patients Compare Favorably with Historical Data in Patients with AL Amyloidosis NEOD001 Continues to be Safe and Well-Tolerated, with No Dose Limiting Toxicities Observed Excellent Pharmacokinetic Properties and No Immunogenicity Currently Enrolling Expansion Portion of Phase 1/2 Trial with New Data Expected to be Presented Annually at Appropriate Medical Conferences, Beginning in 2015 Prothena to Host Investor Conference Call and Webcast Today at 4:30 p.m. ET DUBLIN, Ireland, Dec.
Sign-up for Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis investment picks
MADRID and REDWOOD CITY, Calif, Sept.
Sign-up for OncoMed's Demcizumab Phase 1b Clinical Trials Show Encouraging Safety and Anti-Tumor Activity at ESMO investment picks
Trial Has Not Yet Reached Necessary Number of Survival Events to Report on Overall Survival Due to Longer than Expected Survival of Study Patients LOS ANGELES , Oct.
Sign-up for CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting investment picks
-- Isis Earns $27 Million Milestone Payment --
Sign-up for Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Children With Spinal Muscular Atrophy investment picks
Completion of Enrollment Expected in 2015; Progression-Free Survival Data Expected in mid-2016 LOS ANGELES , Sept.
Sign-up for CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer investment picks
2014/10/10
Phase 3 ENDEAR study in infants with SMA enrolling; on track to initiate Phase 3 study in children with SMA later this year Isis to host a webcast at 11:30 a.m. EDT on Friday, October 10 CARLSBAD, Calif.
Sign-up for Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy investment picks
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced positive top-line results from its Phase 2b placebo-controlled trial of AKB-6548 in non-dialysis patients with anemia related to chronic kidney disease (CKD). The study achieved its primary endpoint and AKB-6548 was generally well tolerated, confirming that the once-daily, oral therapy can successfully increase and maintain hemoglobin (HGB) levels.
Sign-up for Akebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has completed enrollment in its Phase 2 clinical trial with revusiran (re-VOO-si-ran), the recommended International Nonproprietary Name (INN) for ALN-TTRsc.
Sign-up for Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis investment picks
Under the FDA's Generating Antibiotic Incentives Now (GAIN) Act, the Qualified Infectious Disease Product (QIDP) designation allows for additional five years of market exclusivity in addition to existing exclusivity, Fast-Track status (an expedited development pathway) and Priority Review status (shortened review time for marketing applications) With half of the targeted 120 patients already recruited, top-line data from the ongoing RHB-105 first Phase III study in the U.S. is expected in the second quarter of 2015 RHB-105 is targeting a significantly broader indication than that of existing H.
Sign-up for FDA Grants QIDP Fast-Track Designation to RedHill Biopharma's Phase III H. pylori Drug RHB-105 investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today positive initial Phase 2 data with revusiran (ALN-TTRsc), an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR cardiac amyloidosis.
Sign-up for Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients investment picks
The randomized, double-blind, placebo-controlled, parallel group Phase III study with RHB-102 (the GUARD study) will enroll 320 acute gastroenteritis patients in the U.S. Acute gastroenteritis is an inflammation of the gastrointestinal tract causing nausea and vomiting, with a potential worldwide market estimated to exceed $650 million If approved for marketing by the FDA, RHB-102 is expected to be the first-ever 5-HT3 antagonist drug indicated for acute gastroenteritis Dr.
Sign-up for RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis investment picks
Clovis Oncology (NASDAQ:CLVS) today announced preliminary Phase 2 results from the ARIEL2 ( A ssessment of R ucaparib I n Ovarian Canc e r Tria l ) study and updated results from the ongoing Phase 1/2 monotherapy study of rucaparib.
Sign-up for Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy investment picks
Data Presented as Part of Meta-Analysis Showing MM-121's Favorable Impact on Progression Free Survival in 38-54 Percent of Patients With Ovarian, Lung and Breast Cancers Across Three Phase 2 Studies MADRID, Spain, Sept.
Sign-up for Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Research Phase
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Permit  |  Next: Research Pipeline